Nektar Therapeutics (NKTR) Current Ratio
- Current ratio · latest quarter: Value 10.42×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 10.42× | Current assets / current liabilities. $739.40M ÷ $70.98M ≈ 10.42× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 739.40M USD | Assets, Current |
| Current obligations | 70.98M USD | Liabilities, Current |
| Cash and equivalents | 39.27M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 645.07M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | Inventory, Net |
| Payables | 24.89M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $739.40M | $70.98M | $39.27M | $645.07M | (m) | (m) | $24.89M | (m) | 10.42× |
| 2026-03-31 | $589.04M | $57.71M | $149.58M | $419.03M | (m) | (m) | $10.03M | (m) | 10.21× |
| 2025-12-31 | $266.27M | $53.54M | $15.12M | $230.64M | (m) | (m) | $10.77M | (m) | 4.97× |
| 2025-09-30 | $281.36M | $66.34M | $41.03M | $229.18M | (m) | (m) | $15.56M | (m) | 4.24× |
| 2025-06-30 | $186.57M | $71.39M | $42.99M | $132.91M | (m) | (m) | $14.28M | (m) | 2.61× |
| 2025-03-31 | $229.91M | $70.93M | $38.89M | $179.74M | (m) | (m) | $17.83M | (m) | 3.24× |
| 2024-12-31 | $261.29M | $61.40M | $44.25M | $210.97M | (m) | $0.00 | $11.56M | (m) | 4.26× |
| 2024-09-30 | $286.48M | $67.58M | $30.11M | $214.39M | $0.00 | $0.00 | $8.58M | (m) | 4.24× |
| 2024-06-30 | $295.19M | $57.33M | $27.94M | $243.29M | $1.20M | $14.46M | $6.47M | (m) | 5.15× |
| 2024-03-31 | $319.84M | $52.41M | $48.64M | $240.60M | $3.62M | $16.24M | $8.76M | (m) | 6.10× |
| 2023-12-31 | $330.70M | $51.27M | $35.28M | $268.34M | $1.21M | $16.10M | $9.85M | (m) | 6.45× |
| 2023-09-30 | $399.02M | $52.11M | $64.92M | $307.74M | $2.20M | $15.13M | $3.29M | (m) | 7.66× |
| 2023-06-30 | $441.06M | $50.69M | $50.73M | $358.70M | $1.33M | $20.69M | $2.62M | (m) | 8.70× |
| 2023-03-31 | $491.07M | $59.88M | $76.95M | $379.87M | $3.00M | $20.23M | $3.70M | (m) | 8.20× |
| 2022-12-31 | $545.97M | $68.20M | $88.23M | $416.75M | $5.98M | $19.20M | $12.98M | (m) | 8.00× |
| 2022-09-30 | $599.48M | $83.99M | $105.76M | $440.63M | $11.53M | $19.06M | $5.33M | (m) | 7.14× |
| 2022-06-30 | $665.54M | $104.98M | $77.55M | $541.77M | $10.01M | $16.97M | $12.35M | (m) | 6.34× |
| 2022-03-31 | $733.46M | $105.28M | $67.99M | $599.03M | $30.22M | $15.38M | $12.62M | (m) | 6.97× |
| 2021-12-31 | $795.58M | $85.20M | $25.22M | $708.74M | $22.49M | $15.80M | $9.75M | (m) | 9.34× |
| 2021-09-30 | $986.13M | $139.97M | $54.02M | $867.06M | $28.99M | $15.33M | $23.66M | (m) | 7.05× |
| 2021-06-30 | $1.06B | $131.02M | $152.34M | $847.72M | $28.87M | $14.62M | $19.70M | (m) | 8.06× |
| 2021-03-31 | $1.10B | $123.63M | $150.16M | $887.15M | $29.16M | $16.81M | $22.43M | (m) | 8.89× |
| 2020-12-31 | $1.14B | $115.78M | $198.96M | $862.94M | $38.89M | $15.29M | $22.14M | (m) | 9.83× |
| 2020-09-30 | $1.04B | $126.50M | $55.84M | $900.16M | $42.92M | $12.89M | $15.48M | (m) | 8.25× |
| 2020-06-30 | $1.15B | $123.96M | $58.21M | $980.19M | $47.24M | $12.58M | $19.25M | (m) | 9.29× |
| 2020-03-31 | $1.43B | $377.47M | $227.03M | $1.12B | $42.03M | $14.32M | $21.79M | (m) | 3.79× |
| 2019-12-31 | $1.42B | $353.89M | $96.36M | $1.23B | $36.80M | $12.66M | $19.23M | (m) | 4.02× |
| 2019-09-30 | $1.58B | $125.35M | $81.22M | $1.41B | $41.20M | $13.72M | $21.96M | (m) | 12.60× |
| 2019-06-30 | $1.60B | $113.37M | $85.42M | $1.43B | $37.30M | $13.19M | $9.35M | (m) | 14.09× |
| 2019-03-31 | $1.49B | $99.72M | $106.75M | $1.28B | $42.89M | $11.78M | $11.01M | (m) | 14.94× |
| 2018-12-31 | $1.44B | $82.00M | $194.91M | $1.14B | $43.21M | $11.38M | $5.85M | (m) | 17.53× |
| 2018-09-30 | $1.51B | $108.08M | $222.26M | $1.20B | $31.94M | $13.30M | $7.49M | (m) | 13.93× |
| 2018-06-30 | $1.91B | $96.90M | $911.13M | $912.68M | $35.31M | $11.88M | $10.67M | (m) | 19.67× |
| 2018-03-31 | $336.01M | $80.70M | $34.80M | $261.85M | $15.61M | $10.68M | $11.38M | (m) | 4.16× |
| 2017-12-31 | $326.82M | $56.16M | $4.76M | $291.37M | $5.01M | $10.73M | $4.78M | (m) | 5.82× |
| 2017-09-30 | $382.80M | $92.54M | $37.97M | $314.60M | $3.31M | $13.65M | $8.56M | (m) | 4.14× |
| 2017-06-30 | $288.17M | $72.61M | $16.15M | $249.40M | $4.11M | $11.01M | $6.24M | (m) | 3.97× |
| 2017-03-31 | $380.99M | $78.52M | $23.48M | $335.04M | $1.56M | $13.02M | $6.95M | (m) | 4.85× |
| 2016-12-31 | $425.95M | $72.22M | $59.64M | $329.46M | $15.68M | $11.11M | $2.82M | (m) | 5.90× |
| 2016-09-30 | $282.52M | $76.31M | $63.30M | $190.22M | $14.25M | $10.75M | $7.12M | (m) | 3.70× |
| 2016-06-30 | $318.32M | $79.28M | $55.68M | $219.18M | $27.78M | $10.26M | $2.33M | (m) | 4.02× |
| 2016-03-31 | $344.85M | $65.94M | $72.55M | $215.78M | $39.68M | $11.25M | $2.35M | (m) | 5.23× |
| 2015-12-31 | $350.05M | $61.25M | $55.57M | $253.37M | $19.95M | $11.35M | $2.36M | (m) | 5.72× |
| 2015-09-30 | $286.35M | $208.10M | $18.82M | $249.00M | $2.97M | $10.35M | $2.28M | (m) | 1.38× |
| 2015-06-30 | $302.25M | $81.08M | $20.88M | $233.78M | $3.68M | $10.12M | $2.83M | (m) | 3.73× |
| 2015-03-31 | $347.29M | $75.44M | $129.45M | $171.35M | $2.88M | $12.51M | $5.02M | (m) | 4.60× |
| 2014-12-31 | $288.20M | $64.05M | $12.37M | $225.46M | $3.61M | $12.95M | $2.70M | (m) | 4.50× |
| 2014-09-30 | $324.12M | $80.55M | $32.01M | $204.63M | $46.07M | $11.70M | $5.43M | (m) | 4.02× |
| 2014-06-30 | $298.22M | $84.36M | $30.70M | $245.74M | $3.05M | $14.11M | $7.44M | (m) | 3.54× |
| 2014-03-31 | $304.77M | $79.31M | $32.44M | $251.63M | $1.85M | $12.87M | $3.06M | (m) | 3.84× |
| 2013-12-31 | $257.88M | $98.22M | $39.07M | $197.96M | $2.23M | $13.45M | $9.12M | (m) | 2.63× |
| 2013-09-30 | $207.94M | $80.91M | $65.41M | $118.14M | $4.56M | $15.08M | $3.72M | (m) | 2.57× |
| 2013-06-30 | $234.42M | $90.28M | $41.43M | $160.45M | $6.04M | $20.48M | $5.57M | (m) | 2.60× |
| 2013-03-31 | $267.04M | $83.22M | $28.53M | $207.66M | $3.65M | $18.38M | $4.22M | (m) | 3.21× |
| 2012-12-31 | $314.63M | $78.54M | $25.44M | $251.76M | $5.80M | $18.27M | $2.86M | (m) | 4.01× |
| 2012-09-30 | $346.94M | $69.47M | $10.34M | $308.94M | $3.91M | $16.75M | $2.62M | (m) | 4.99× |
| 2012-06-30 | $468.29M | $276.86M | $136.15M | $296.72M | $11.36M | $14.71M | $3.12M | (m) | 1.69× |
| 2012-03-31 | $420.65M | $270.75M | $148.49M | $233.62M | $10.80M | $14.11M | $1.76M | (m) | 1.55× |
| 2011-12-31 | $276.71M | $275.53M | $15.31M | $225.86M | $4.94M | $12.66M | $3.02M | (m) | 1.00× |
| 2011-09-30 | $297.62M | $279.04M | $43.01M | $223.48M | $12.91M | $10.65M | $2.17M | (m) | 1.07× |
| 2011-06-30 | $389.10M | $61.27M | $11.63M | $351.28M | $8.46M | $9.80M | $3.24M | (m) | 6.35× |
| 2011-03-31 | $539.37M | $58.88M | $22.48M | $496.16M | $2.16M | $11.71M | $3.48M | (m) | 9.16× |
| 2010-12-31 | $353.98M | $64.11M | $17.75M | $298.18M | $25.10M | $7.27M | $7.19M | (m) | 5.52× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |